

## Oncotype DX Genomic Prostate Score® (GPS™) assay

# Understand your test results

Deciding between active surveillance and immediate treatment for your prostate cancer is important. Your GPS™ result may help.


The GPS test measures prostate cancer gene expression to assess how aggressively your cancer will grow or spread. Since certain key genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.

### Your personal GPS result

The bell curve illustrates where your GPS result falls in relation to the GPS results of other men in the same risk category.

#### SAMPLE REPORT:

Patient's GPS result is 12



### Current and future risk

These results can predict both your chance of: **1 your cancer spreading (metastasis)** and **2 dying from prostate cancer** in the next 10 years.


#### SAMPLE REPORT:

	ADVERSE OUTCOME	LIKELIHOOD OF ADVERSE OUTCOME
<b>1</b>	Metastasis Within 10 Years after Radical Prostatectomy <sup>(g)</sup>	<div style="display: flex; align-items: center;"> <div style="border: 1px solid black; padding: 5px; margin-right: 10px;">1%</div> <div style="flex-grow: 1; position: relative;"> <div style="position: absolute; top: -10px; left: 50%; transform: translate(-50%, -100%);">                     (95% CI: &lt;1% - 6%)                 </div> <div style="position: absolute; bottom: -10px; left: 0; width: 100%;"> <span style="position: absolute; left: 0; bottom: 0;">0%</span> <span style="position: absolute; right: 0; bottom: 0;">100%</span> </div> </div> </div>
<b>2</b>	Prostate Cancer Death Within 10 Years After Radical Prostatectomy	<div style="display: flex; align-items: center;"> <div style="border: 1px solid black; padding: 5px; margin-right: 10px;">&lt;1%</div> <div style="flex-grow: 1; position: relative;"> <div style="position: absolute; top: -10px; left: 50%; transform: translate(-50%, -100%);">                     (95% CI: &lt;1% - &lt;1%)                 </div> <div style="position: absolute; bottom: -10px; left: 0; width: 100%;"> <span style="position: absolute; left: 0; bottom: 0;">0%</span> <span style="position: absolute; right: 0; bottom: 0;">100%</span> </div> </div> </div>

Oncotype DX Genomic Prostate Score, Genomic Prostate Score, and GPS are trademarks of Genomic Health, Inc. a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. All other trademarks are the properties of their respective owners. ©2022 Genomic Health, Inc. All rights reserved. M-US-GPS-00357


# Oncotype DX Genomic Prostate Score® (GPS™) assay

## Personalized assessment for individualized treatment



SCAN TO  
LEARN MORE

**3 Adverse Pathology** predicts the probability your doctor would find more aggressive disease than expected from your biopsy. This helps your doctor know if you are a candidate for active surveillance or if immediate treatment is best for you.




Radical prostatectomy is an operation to remove the prostate gland and tissues surrounding it. All patients in the clinical validation studies were treated with radical prostatectomy.

### Additional pathology endpoints

**1 High-Grade Disease** shows the likelihood that cancer cells within your tumor are abnormal when compared to typical cells. **2 Non-Organ-Confined Disease** indicates the likelihood that your cancer has already spread outside your prostate.

### SAMPLE REPORT:



The GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.<sup>1</sup>

Reference: 1. Badani et al. *Urol Pract.* 2015.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Prostate Cancer V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed (March 10, 2022). To view the most recent and complete version of the guideline, go online to NCCN.org.

Oncotype DX Genomic Prostate Score, Genomic Prostate Score, and GPS are trademarks of Genomic Health, Inc. a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. All other trademarks are the properties of their respective owners. ©2022 Genomic Health, Inc. All rights reserved. M-US-GPS-00357